

Dr. Jason YANG 杨建新

CEO, President of R&D and Executive Director of the Board
CStone Pharmaceuticals

A seasoned biopharma leader with over 30 years of experience driving end-to-end drug development—from discovery and translational research through clinical development and commercialization.

Key Achievements:

- Successfully led the development and marketing of four novel oncology therapies in Greater China (sugemalimab, avapritinib, pralsetinib, ivosidenib) at CStone, secured EU/UK regulatory approval for sugemalimab in 2024, and established four commercial partnerships spanning over 60 countries.
- Built and advanced a global-facing, next-generation Pipeline 2.0, featuring innovative assets such as CS2009 (a potential first-in-class PD-1/VEGF/CTLA-4 trispecific antibody) and CS5001 (a best-in-class contender ROR1 ADC), alongside other promising ADC and autoimmune/inflammatory candidates.
- Established and led clinical development and operations functions as SVP/Head of Clinical Development at BeiGene, leading global development for four key oncology assets (PD-1, BTKi, PARPi, RAFi) and managing 10+ trials from first-in-human to registrational studies.
- Authored 80+ peer-reviewed publications and presentations in high-impact journals including JAMA, Nature Medicine, The Lancet Oncology, JCO, Nature Cancer, and Clinical Cancer Research, and holds 16 patents.

Education:

- MD training from Hubei Medical College and Nanjing Medical University;
- PhD from UT Southwestern Medical Center under Nobel Laureates Michael S. Brown and Joseph L. Goldstein; Postdoctoral training at Harvard University with Stuart Schreiber.